Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
BackgroundThis placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2)-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). MethodsPatients (n=27) were randomized to FF (100g), VI (25g), FF/VI (100/25g), and placebo for 21days (four periods). Allerg
